| List of products supplied under the CSL Australian Fractionation Agreement | ||
| Supplier | Product type/trade name |
Clinical use approved under the National Blood Arrangements |
|---|---|---|
| CSL Limited | Albumin | |
| Albumex 4 | Used to treat hypovolaemia arising from shock, surgery or multiple organ failure | |
| Albumex 20 | Used to treat patients suffering extensive burns or shock due to blood loss, or kidney or liver disease | |
| Immunoglobulins | ||
| Hyperimmune globulins | Used to prevent a specific infection such as tetanus, hepatitis B, Zoster or cytomegalovirus | |
| Intragam P | Used to reduce susceptibility to infections and manage many immune system disorders | |
| Rh (D) Immunoglobulin | Used in the prevention of haemolytic disease of the newborn (HDNB), a potentially fatal form of anaemia in newborn babies of Rh (D) negative mothers | |
| Clotting factors | ||
| Biostate | Used in the treatment of bleeding episodes in patients with FVIII deficiency due to haemophilia A. Biostate is also used in the treatment of bleeding episodes in patients with von Willebrand disease. | |
| MonoFIX-VF | Used in the treatment of bleeding episodes in patients with Factor IX deficiency, known as haemophilia B or Christmas disease | |
| Prothrombinex-VF | Used to manage patients who need warfarin reversal for urgent surgery and treatment of some bleeding episodes in patients who have factor deficiency II, IX and X when a more purified factor concentrate is not available |
|
| Thrombotrol-VF | Used to manage an inherited condition wherein a patient’s blood clots too quickly | |
| List of imported IVIg products | ||
| Supplier | Product type/trade name |
Clinical use approved under the National Blood Arrangements or Jurisdictional Blood Orders |
| Octapharma Australia | Octagam | Used to reduce susceptibility to infections and manage many immune system disorders (not available September 2010–June 2011) |
| Lateral Diagnostics | Flebogamma | Used to reduce susceptibility to infections and manage many immune system disorders (available for Jurisdictional Direct Orders) and under the National Blood Arrangements in defined circumstances |
| List of imported rare bleeding and blood disorder plasma products | ||
| Baxter Healthcare | Anti Inhibitor Coagulant Complex Concentrates/FEIBA | Used in the treatment of bleeding episodes including surgical interventions in haemophilia A and B patients with inhibitors |
| FVII concentrate | Used in the treatment of bleeding episodes in people with Factor VII deficiency | |
| Protein C/Ceprotin | Used in the treatment of haemorrhagic conditions associated with congenital Protein C deficiency | |
| WinRho | Used in the prevention of a potentially fatal form of anaemia in newborn babies of Rh (D) negative mothers | |
| CSL Limited | FXI/BPL Factor XI | Used in the treatment of bleeding episodes in people with Factor XI deficiency (sometimes called haemophilia C) |
| FXIII/Fibrogammin P | Used in the treatment of bleeding episodes in people with Factor XIII deficiency | |
| List of imported rare bleeding and blood disorder recombinant products | ||
| Supplier | Product type/trade name |
Clinical use approved under the National Blood Arrangements |
| Novo Nordisk Pharmaceuticals | rFVIIa/NovoSeven | Used in the treatment of bleeding episodes including surgical intervention in haemophilia A or B patients with inhibitors to Factor VIII or Factor IX |
| Baxter Healthcare Pty Ltd | rFVIII/Recombinate | Used in the prevention and control of haemorrhagic episodes in haemophilia A (Factor VIII deficiency) patients |
| rFVIII/Advate | Used in the prevention and control of haemorrhagic episodes in haemophilia A (Factor VIII deficiency) patients | |
| Wyeth Australia Pty Ltd | rFVIII/Refacto/Xyntha | Used in the prevention and control of haemorrhagic episodes in haemophilia A (Factor VIII deficiency) patients |
| rFIX/BeneFIX | Used in the prevention and control of haemorrhagic episodes in haemophilia B or Christmas disease (Factor IX deficiency) patients | |